Related Experiment Videos
Inhaled glucocorticoid therapy in infants at risk for neonatal chronic lung disease
1Boston Floating Hospital for Children, New England Medical Center, Tufts University School of Medicine, Massachusetts 02111, USA.
Insights
Inhaled glucocorticoid therapy offers potential benefits for neonatal chronic lung disease (CLD) with few adverse effects. Further research is needed to optimize delivery and confirm efficacy in preventing and treating CLD in infants.
Area of Science:
- Neonatal Medicine
- Pulmonology
- Pharmacology
Background:
- Neonatal chronic lung disease (CLD) presents a significant challenge, necessitating effective anti-inflammatory treatments with minimal side effects.
- Systemic glucocorticoid therapy, while effective, carries risks, driving the search for safer alternatives like inhaled glucocorticoids.
Purpose of the Study:
- To evaluate the efficacy and safety of inhaled glucocorticoid therapy for the treatment and prevention of neonatal chronic lung disease (CLD).
- To explore the potential of inhaled glucocorticoids as an alternative to systemic therapies, aiming for improved respiratory outcomes in infants.
Main Methods:
- Review of initial reports and recent randomized controlled trials investigating inhaled glucocorticoid therapy in infants with CLD.
- Analysis of studies comparing pulmonary response to inhaled versus systemic glucocorticoid administration.
- Assessment of reported adverse effects associated with inhaled glucocorticoid therapy.
Main Results:
- Initial studies suggest modest improvements in neonatal respiratory outcomes with inhaled glucocorticoid therapy.
- Recent trials indicate potential benefits but have not yet demonstrated a significant reduction in CLD incidence.
- Few adverse effects have been noted, but uncertainty remains regarding optimal dose delivery and deposition.
Conclusions:
- Inhaled glucocorticoid therapy shows promise for neonatal CLD treatment and prevention, with a favorable safety profile.
- Further research is warranted to address limitations in aerosol delivery and deposition, and to confirm clinical benefits.
- Advances in drug delivery devices and formulations are expected to enhance the efficacy of inhaled glucocorticoid therapy for infants.
Abstract:
The primary impetus for the study of inhaled glucocorticoid therapy in the treatment and prevention of neonatal chronic lung disease (CLD) was to achieve effective anti-inflammatory therapy with few adverse effects. Initial reports of inhaled glucocorticoid therapy in infants with established CLD suggest modest improvement in neonatal respiratory outcomes. Recent randomized trials also indicate that inhaled glucocorticoid therapy may provide some benefit, but have not demonstrated a reduction in CLD. Some studies suggest that the pulmonary response to systemic glucocorticoid may be greater and faster than response to inhaled glucocorticoid therapy. Few adverse effects have been noted with inhaled glucocorticoid therapy. One limitation of studies of inhaled glucocorticoid therapy is the uncertainty of the dose delivered and deposited in peripheral airways and regions of the lungs. Experience with and systematic study of inhaled glucocorticoid therapy is still in its early stages. The role of inhaled glucocorticoid therapy in the treatment and prevention of CLD is evolving. Advances in delivery devices and new developments of drug formulations should improve aerosol delivery and deposition in infants. Given the clinical dilemma of systemic glucocorticoid therapy and potential benefits demonstrated by recent trials of inhaled glucocorticoid therapy, further study of inhaled glucocorticoid therapy for CLD is warranted.